title: Secukinumab: first global approval.
abstract: Secukinumab (Cosentyx™) is a fully human monoclonal antibody against interleukin-17A, formulated for intravenous and subcutaneous administration. It received its first global approval in Japan on 26 December 2014 for the treatment of psoriasis and psoriatic arthritis in adults who are not adequately responding to systemic therapies (except for biologic agents). In the USA and the EU, secukinumab was approved in early 2015 for the treatment of patients with moderate-to-severe plaque psoriasis. Secukinumab is also being investigated in patients with ankylosing spondylitis and rheumatoid arthritis. This article summarizes the milestones in the development of secukinumab leading to its first approval for the treatment of adult patients with psoriasis and psoriatic arthritis.
authors: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
authors: Mark
authors: M
authors: Sanford
authors: Kate
authors: K
authors: McKeage
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005062:European Union; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000276:immunology; D014481:United States; D014605:Uveitis / Q000188:drug therapy / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; C555450:secukinumab
references: J Dermatol. 2014 Dec;41(12 ):1039-46
references: 25354738
references: J Dermatolog Treat. 2015 Feb;26(1):23-31
references: 24354461
references: Ophthalmology. 2013 Apr;120(4):777-87
references: 23290985
references: Gut. 2012 Dec;61(12):1693-700
references: 22595313
references: N Engl J Med. 2014 Jul 24;371(4):326-38
references: 25007392
references: Br J Dermatol. 2015 Feb;172(2):484-93
references: 25132411
references: Ann Rheum Dis. 2013 Jun;72(6):863-9
references: 22730366
references: Clin Cosmet Investig Dermatol. 2014 Sep 15;7:251-9
references: 25246805
references: Health Qual Life Outcomes. 2014 Mar 05;12:31
references: 24597620
references: Br J Dermatol. 2013 Feb;168(2):402-11
references: 23362969
references: Clin Vaccine Immunol. 2012 Oct;19(10):1597-602
references: 22875601
references: BioDrugs. 2013 Aug;27(4):359-73
references: 23580094
references: Lancet. 2013 Nov 23;382(9906):1705-13
references: 24035250
references: Br J Dermatol. 2013 Feb;168(2):412-21
references: 23106107
references: J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90
references: 25243910